Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Massachusetts General Hospital Cancer Center, Boston, MA, United States

Survival: 43.9 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Massachusetts General Hospital Cancer Center
Journal: Link
Date: 1/2012

This phase 3 study involved 716 men with castration-resistant prostate cancer. The median patient age was 74 years.

Patients were treated with the biologic therapy agent denosumab, which is a monoclonal antibody that inactivates a protein called RANKL and subsequently works to prevent bone metastases commonly associated with prostate cancer.

Treatment-related deaths were reported, but specific causes were not given. Severe anemia, urinary tract infection, and loss of bone density were reported.

The reported median overall survival was 43.9 months.

This study was supported by Amgen, makers of denosumab.

Correspondence: Dr. Matthew R Smith; email:

E-mail to a Friend Email Physician More Information